EHA 2020

Listen

The Annual Congress of EHA is a flagship meeting held in a major European city every June— a significant meeting place for haematologists from across the world including Australia. This annual conference encompasses the entire spectrum of haematological studies including Lymphoma and CLL.

Due to the massive worldwide impact of the COVID-19 crisis, the 25th Congress of the European Hematology Association (EHA) was replaced by a virtual edition.

Lymphoma Australia was honoured to have the opportunity to interview some of our expert clinicians in Australia who provided their reviews of papers, research, and presentations – and how this relates to Australian patients.

On behalf of the Lymphoma / CLL community we would also like to take this opportunity to thank everyone for their time. Knowledge is power.

EHA 2020 Congress - Aggressive lymphoma updates

EHA 2020 Congress - Indolent lymphoma updates

EHA 2020 Congress - Classical Hodgkin Lymphoma

EHA 2020 Congress - Mantle cell lymphoma & Waldenstrom’s macroglobulinemia highlights

EHA 2020 Congress - ASPEN study for Waldenstrom’s macroglobulinemia

EHA 2020 congress - Long term results from the Gallium study for follicular lymphoma

EHA 2020 congress - Zanubrutinib for Waldenstrom’s macroglobulinemia

Sign up to our Newsletter

Lymphoma Australia is the only incorporated charity in Australia dedicated to solely providing education, support, awareness and advocacy initiatives for Australians touched by lymphoma and chronic lymphocytic leukemia (CLL).

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
Relapsed: This means the lymphoma came back after being gone for a while after treatment.
2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here.

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.